PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för naxagolide hydrochloride. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

8 hits

Bibliografisk träff 2005-06-01

Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.

Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm050155n

Bibliografisk träff 1993-09-01

Poor tolerability of MK-458.

Cutler NR, Sramek JJ, Block GA.

Arch Neurol · letter; comment · DOI 10.1001/archneur.1993.00540090007003

Bibliografisk träff 1992-05-01

Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)

Ahlskog JE, Muenter MD, Bailey PA, Stevens PM.

Arch Neurol · research support, non-u.s. gov't; journal article · DOI 10.1001/archneur.1992.00530290152026

Bibliografisk träff 1992-03-01

Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.

Cutler NR, Reines SA, McLean LF, Sramek JJ, Porras AG, Hand EL.

Clin Pharmacokinet · journal article · DOI 10.2165/00003088-199222030-00004

Bibliografisk träff 1991-08-01

Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.

Koller WC, Block GA, Ahlskog JE, Ahrens S, Cedarbaum JM, Cyhan G, Goetz CG, LeWitt PA, Liss C, McLean L.

Clin Neuropharmacol · clinical trial; multicenter study; randomized controlled trial; journal article · DOI 10.1097/00002826-199108000-00004

Bibliografisk träff 1991-06-01

Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.

Ahlskog JE, Muenter MD, Bailey PA, Miller PM.

Clin Neuropharmacol · comparative study; clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1097/00002826-199106000-00004

Bibliografisk träff 1990-01-01

Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.

Cedarbaum JM, Clark M, Toy LH, Green-Parsons A.

Mov Disord · comparative study; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1002/mds.870050407

Bibliografisk träff 1988-06-01

MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.

Lieberman A, Chin L, Baumann G.

Clin Neuropharmacol · research support, non-u.s. gov't; journal article · DOI 10.1097/00002826-198806000-00001